SPA
PTCT icon

Sherbrooke Park Advisers’s PTC Therapeutics PTCT Stock Holding History

Sherbrooke Park Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,028
Closed -$343K – 685
2025
Q2 		$343K Buy
7,028
+1,646
+31% +$78.1K 0.15% 279
2025
Q1 		$274K Buy
+5,382
New +$269K 0.13% 328
2024
Q3 		– Sell
-6,630
Closed -$203K – 1188
2024
Q2 		$203K Buy
+6,630
New +$215K 0.04% 768

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's PTCT Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 7,028 shares — an estimated $343K sold.

Sherbrooke Park Advisers first reported a position in PTCT in Q2 2024 and held it in 3 quarters. The position peaked at $343K in Q2 2025. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 7,028 PTC Therapeutics shares in Q3 2025, an estimated $343K.
  • Sherbrooke Park Advisers first reported a position in PTC Therapeutics in Q2 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's PTC Therapeutics position peaked at $343K in Q2 2025.
  • 294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.